Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors

Kim Long Yeo, Yen Liang Chen, Hao Ying Xu, Hongping Dong, Qing Yin Wang, Fumiaki Yokokawa, Pei-Yong Shi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new treatments for infectious pathogens. In this study, we performed a combination treatment in cell culture by using three distinct classes of inhibitors, including ribavirin (a guanosine analog with several antiviral mechanisms), brequinar (a pyrimidine biosynthesis inhibitor), and INX-08189 (a guanosine analog). The compound pairs were evaluated for antiviral activity by use of a DENV-2 luciferase replicon assay. Our result indicated that the combination of ribavirin and INX- 08189 exhibited strong antiviral synergy. This result suggests that synergy can be achieved with compound pairs in which one compound suppresses the synthesis of the nucleoside for which the other compound is a corresponding nucleoside analog. In addition, we found that treatment of cells with brequinar alone could activate interferon-stimulated response elements (ISREs); furthermore, brequinar and NITD-982 (another pyrimidine biosynthesis inhibitor) potentiated interferon-induced ISRE activation. Compared to treatment with brequinar, treatment of cells with ribavirin alone could also induce ISRE activation, but to a lesser extent; however, when cells were cotreated with ribavirin and beta interferon, ribavirin did not augment the interferoninduced ISRE activation.

Original languageEnglish (US)
Pages (from-to)2086-2093
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

brequinar
Dengue Virus
Ribavirin
Virus Replication
Nucleosides
Interferons
Antiviral Agents
Response Elements
Guanosine
Replicon
Interferon-beta
Culicidae
Luciferases
Vaccines
Cell Culture Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases
  • Medicine(all)

Cite this

Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. / Yeo, Kim Long; Chen, Yen Liang; Xu, Hao Ying; Dong, Hongping; Wang, Qing Yin; Yokokawa, Fumiaki; Shi, Pei-Yong.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 4, 01.04.2015, p. 2086-2093.

Research output: Contribution to journalArticle

Yeo, Kim Long ; Chen, Yen Liang ; Xu, Hao Ying ; Dong, Hongping ; Wang, Qing Yin ; Yokokawa, Fumiaki ; Shi, Pei-Yong. / Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 4. pp. 2086-2093.
@article{90c943faf1244292bafa9d4bb78670ec,
title = "Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors",
abstract = "Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new treatments for infectious pathogens. In this study, we performed a combination treatment in cell culture by using three distinct classes of inhibitors, including ribavirin (a guanosine analog with several antiviral mechanisms), brequinar (a pyrimidine biosynthesis inhibitor), and INX-08189 (a guanosine analog). The compound pairs were evaluated for antiviral activity by use of a DENV-2 luciferase replicon assay. Our result indicated that the combination of ribavirin and INX- 08189 exhibited strong antiviral synergy. This result suggests that synergy can be achieved with compound pairs in which one compound suppresses the synthesis of the nucleoside for which the other compound is a corresponding nucleoside analog. In addition, we found that treatment of cells with brequinar alone could activate interferon-stimulated response elements (ISREs); furthermore, brequinar and NITD-982 (another pyrimidine biosynthesis inhibitor) potentiated interferon-induced ISRE activation. Compared to treatment with brequinar, treatment of cells with ribavirin alone could also induce ISRE activation, but to a lesser extent; however, when cells were cotreated with ribavirin and beta interferon, ribavirin did not augment the interferoninduced ISRE activation.",
author = "Yeo, {Kim Long} and Chen, {Yen Liang} and Xu, {Hao Ying} and Hongping Dong and Wang, {Qing Yin} and Fumiaki Yokokawa and Pei-Yong Shi",
year = "2015",
month = "4",
day = "1",
doi = "10.1128/AAC.04779-14",
language = "English (US)",
volume = "59",
pages = "2086--2093",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors

AU - Yeo, Kim Long

AU - Chen, Yen Liang

AU - Xu, Hao Ying

AU - Dong, Hongping

AU - Wang, Qing Yin

AU - Yokokawa, Fumiaki

AU - Shi, Pei-Yong

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new treatments for infectious pathogens. In this study, we performed a combination treatment in cell culture by using three distinct classes of inhibitors, including ribavirin (a guanosine analog with several antiviral mechanisms), brequinar (a pyrimidine biosynthesis inhibitor), and INX-08189 (a guanosine analog). The compound pairs were evaluated for antiviral activity by use of a DENV-2 luciferase replicon assay. Our result indicated that the combination of ribavirin and INX- 08189 exhibited strong antiviral synergy. This result suggests that synergy can be achieved with compound pairs in which one compound suppresses the synthesis of the nucleoside for which the other compound is a corresponding nucleoside analog. In addition, we found that treatment of cells with brequinar alone could activate interferon-stimulated response elements (ISREs); furthermore, brequinar and NITD-982 (another pyrimidine biosynthesis inhibitor) potentiated interferon-induced ISRE activation. Compared to treatment with brequinar, treatment of cells with ribavirin alone could also induce ISRE activation, but to a lesser extent; however, when cells were cotreated with ribavirin and beta interferon, ribavirin did not augment the interferoninduced ISRE activation.

AB - Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new treatments for infectious pathogens. In this study, we performed a combination treatment in cell culture by using three distinct classes of inhibitors, including ribavirin (a guanosine analog with several antiviral mechanisms), brequinar (a pyrimidine biosynthesis inhibitor), and INX-08189 (a guanosine analog). The compound pairs were evaluated for antiviral activity by use of a DENV-2 luciferase replicon assay. Our result indicated that the combination of ribavirin and INX- 08189 exhibited strong antiviral synergy. This result suggests that synergy can be achieved with compound pairs in which one compound suppresses the synthesis of the nucleoside for which the other compound is a corresponding nucleoside analog. In addition, we found that treatment of cells with brequinar alone could activate interferon-stimulated response elements (ISREs); furthermore, brequinar and NITD-982 (another pyrimidine biosynthesis inhibitor) potentiated interferon-induced ISRE activation. Compared to treatment with brequinar, treatment of cells with ribavirin alone could also induce ISRE activation, but to a lesser extent; however, when cells were cotreated with ribavirin and beta interferon, ribavirin did not augment the interferoninduced ISRE activation.

UR - http://www.scopus.com/inward/record.url?scp=84949114816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949114816&partnerID=8YFLogxK

U2 - 10.1128/AAC.04779-14

DO - 10.1128/AAC.04779-14

M3 - Article

VL - 59

SP - 2086

EP - 2093

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -